A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts
- 12 December 2000
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 24 (2), 197-209
- https://doi.org/10.1016/s0731-7085(00)00397-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- HPLC−Accelerator MS Measurement of Atrazine Metabolites in Human Urine after Dermal ExposureAnalytical Chemistry, 1999
- Analytical Performance of Accelerator Mass Spectrometry and Liquid Scintillation Counting for Detection of 14C-Labeled Atrazine Metabolites in Human UrineAnalytical Chemistry, 1998
- Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 miceCarcinogenesis: Integrative Cancer Research, 1997
- Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometryChemico-Biological Interactions, 1997
- MeIQx-DNA adduct formation in rodent and human tissues at low dosesMutation Research, 1997
- Accelerator mass spectrometryAnalytical Chemistry, 1995
- Dose-response studies of MeIQx in rat liver and liver DNA at low dosesCarcinogenesis: Integrative Cancer Research, 1995
- Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA.Proceedings of the National Academy of Sciences, 1990
- Radiocarbon Dating Using Electrostatic Accelerators: Negative Ions Provide the KeyScience, 1977
- Carbon-14: Direct Detection at Natural ConcentrationsScience, 1977